U.S. markets open in 5 hours 59 minutes

ShockWave Medical, Inc. (SWAV)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
73.65+1.70 (+2.36%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close71.95
Bid0.00 x 800
Ask0.00 x 800
Day's Range72.13 - 74.07
52 Week Range22.01 - 74.07
Avg. Volume463,820
Market Cap2.504B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.12
Earnings DateNov 05, 2020 - Nov 09, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est68.20
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Shockwave Medical to Participate in Upcoming September Investor Conferences

    SANTA CLARA, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that Shockwave management is scheduled to speak at the following upcoming virtual investor conferences: * The 2020 Wells Fargo Virtual Healthcare Conference, Wednesday, September 9, 2020, at 2:40 p.m. Eastern Time   * The Morgan Stanley Virtual 18th Annual Global Healthcare Conference, Thursday, September 17, 2020, at 2:45 p.m. Eastern Time             Interested parties may access live and archived webcasts of these events on the "Investors" section of the company’s website at https://ir.shockwavemedical.com.About Shockwave Medical, Inc. Shockwave Medical is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The company aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which the company refers to as Intravascular Lithotripsy (IVL). IVL is a minimally invasive, easy-to-use and safe way to significantly improve patient outcomes. To view an animation of the IVL procedure and for more information, visit www.shockwavemedical.com.Media Contact: Scott Shadiow +1.317.432.9210 sshadiow@shockwavemedical.comInvestor Contact: Debbie Kaster investors@shockwavemedical.com

  • ShockWave Medical Inc (SWAV) Q2 2020 Earnings Call Transcript
    Motley Fool

    ShockWave Medical Inc (SWAV) Q2 2020 Earnings Call Transcript

    Joining me are Doug Godshall, president and chief executive officer of ShockWave Medical; and Dan Puckett, chief financial officer of ShockWave Medical. Earlier today, ShockWave released financial results for the quarter ended June 30, 2020.

  • Benzinga

    ShockWave Medical: Q2 Earnings Insights

    Shares of ShockWave Medical (NASDAQ:SWAV) moved higher by 1.5% in after-market trading after the company reported Q2 results.Quarterly Results Earnings per share decreased 47.37% over the past year to ($0.56), which beat the estimate of ($0.62).Revenue of $10,286,000 rose by 2.74% from the same period last year, which beat the estimate of $8,350,000.Guidance Earnings guidance hasn't been issued by the company for now.Revenue guidance hasn't been issued by the company for now.Details Of The Call Date: Aug 11, 2020View more earnings on SWAVTime: 04:30 PMET Webcast URL: https://edge.media-server.com/mmc/p/i7rw4ij5Recent Stock Performance 52-week high: $53.3352-week low: $22.01Price action over last quarter: Up 31.02%Company Profile ShockWave Medical Inc a medical device company focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. Its intravascular lithotripsy technology is used in the treatment of calcified plaque. Geographically, the company generates its revenue from the United States.See more from Benzinga * Earnings Scheduled For August 11, 2020 * Stocks That Hit 52-Week Highs On Friday * Stocks That Hit 52-Week Highs On Thursday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.